JPWO2020012423A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020012423A5 JPWO2020012423A5 JP2021500540A JP2021500540A JPWO2020012423A5 JP WO2020012423 A5 JPWO2020012423 A5 JP WO2020012423A5 JP 2021500540 A JP2021500540 A JP 2021500540A JP 2021500540 A JP2021500540 A JP 2021500540A JP WO2020012423 A5 JPWO2020012423 A5 JP WO2020012423A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- disorder
- formula
- dioxo
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 66
- 208000035475 disorder Diseases 0.000 claims 58
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 28
- 208000028017 Psychotic disease Diseases 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 17
- -1 bicyclo [3.1.0] hexanyl Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000002619 bicyclic group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000002950 monocyclic group Chemical group 0.000 claims 13
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 12
- 206010012289 Dementia Diseases 0.000 claims 12
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 11
- 208000010877 cognitive disease Diseases 0.000 claims 10
- 229920006395 saturated elastomer Polymers 0.000 claims 10
- 208000019116 sleep disease Diseases 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 229920002401 polyacrylamide Polymers 0.000 claims 9
- 208000019901 Anxiety disease Diseases 0.000 claims 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 8
- 201000000980 schizophrenia Diseases 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000004452 carbocyclyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 6
- 208000029560 autism spectrum disease Diseases 0.000 claims 6
- 230000003542 behavioural effect Effects 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000001568 sexual effect Effects 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 6
- 208000011117 substance-related disease Diseases 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 206010003805 Autism Diseases 0.000 claims 4
- 208000020706 Autistic disease Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- 208000030814 Eating disease Diseases 0.000 claims 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 4
- 206010020710 Hyperphagia Diseases 0.000 claims 4
- 208000019022 Mood disease Diseases 0.000 claims 4
- 201000001880 Sexual dysfunction Diseases 0.000 claims 4
- 230000005856 abnormality Effects 0.000 claims 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 230000001066 destructive effect Effects 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 4
- 231100000872 sexual dysfunction Toxicity 0.000 claims 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 3
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 claims 3
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 239000002439 beta secretase inhibitor Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 3
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 3
- 229960004502 levodopa Drugs 0.000 claims 3
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims 2
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims 2
- 208000036640 Asperger disease Diseases 0.000 claims 2
- 201000006062 Asperger syndrome Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020446 Cardiac disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 2
- 208000030663 Libido disease Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000003863 Marijuana Abuse Diseases 0.000 claims 2
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 206010040981 Sleep attacks Diseases 0.000 claims 2
- 208000027520 Somatoform disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 2
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 2
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 2
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000028505 alcohol-related disease Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 229960001948 caffeine Drugs 0.000 claims 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 208000013677 cerebrovascular dementia Diseases 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 230000006999 cognitive decline Effects 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000000147 hypnotic effect Effects 0.000 claims 2
- 208000000509 infertility Diseases 0.000 claims 2
- 230000036512 infertility Effects 0.000 claims 2
- 231100000535 infertility Toxicity 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 201000010901 lateral sclerosis Diseases 0.000 claims 2
- 210000003141 lower extremity Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000001272 neurogenic effect Effects 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000024309 orgasm disease Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 208000027753 pain disease Diseases 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 208000022821 personality disease Diseases 0.000 claims 2
- 208000007100 phencyclidine abuse Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 239000000932 sedative agent Substances 0.000 claims 2
- 230000001624 sedative effect Effects 0.000 claims 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 2
- 208000015891 sexual disease Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical class CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims 1
- 239000012346 acetyl chloride Substances 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024020524A JP2024056879A (ja) | 2018-07-13 | 2024-02-14 | チアジアジン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1800249 | 2018-07-13 | ||
| HUP1800249A HU231414B1 (hu) | 2018-07-13 | 2018-07-13 | Tiadiazin származékok |
| PCT/IB2019/055949 WO2020012423A1 (en) | 2018-07-13 | 2019-07-12 | Thiadiazine derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024020524A Division JP2024056879A (ja) | 2018-07-13 | 2024-02-14 | チアジアジン誘導体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021529813A JP2021529813A (ja) | 2021-11-04 |
| JP2021529813A5 JP2021529813A5 (https=) | 2022-07-20 |
| JPWO2020012423A5 true JPWO2020012423A5 (https=) | 2022-07-20 |
| JP7440486B2 JP7440486B2 (ja) | 2024-02-28 |
Family
ID=89992726
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500540A Active JP7440486B2 (ja) | 2018-07-13 | 2019-07-12 | チアジアジン誘導体 |
| JP2024020524A Withdrawn JP2024056879A (ja) | 2018-07-13 | 2024-02-14 | チアジアジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024020524A Withdrawn JP2024056879A (ja) | 2018-07-13 | 2024-02-14 | チアジアジン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12194050B2 (https=) |
| EP (1) | EP3820865A1 (https=) |
| JP (2) | JP7440486B2 (https=) |
| KR (1) | KR20210033003A (https=) |
| CN (1) | CN112424198A (https=) |
| AR (1) | AR115783A1 (https=) |
| AU (1) | AU2019300515B2 (https=) |
| BR (1) | BR112020027016A2 (https=) |
| CA (1) | CA3104264A1 (https=) |
| CL (1) | CL2021000081A1 (https=) |
| CO (1) | CO2021001224A2 (https=) |
| CU (1) | CU24622B1 (https=) |
| EA (1) | EA202190246A1 (https=) |
| GE (2) | GEAP202215558A (https=) |
| HU (1) | HU231414B1 (https=) |
| IL (1) | IL279939B2 (https=) |
| MX (1) | MX2021000461A (https=) |
| MY (1) | MY207757A (https=) |
| PE (1) | PE20210465A1 (https=) |
| PH (1) | PH12021550007A1 (https=) |
| SG (1) | SG11202012769QA (https=) |
| TW (1) | TWI827628B (https=) |
| WO (1) | WO2020012423A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4103191A4 (en) * | 2020-02-14 | 2024-03-06 | University of Pittsburgh - of the Commonwealth System of Higher Education | HEAT SHOCK PROTEIN MODULATORS AND THERAPEUTIC AGENTS FOR HUNTINGTON'S DISEASE |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| CN111454232B (zh) * | 2020-05-30 | 2021-11-23 | 南方医科大学 | 一种1,3,4-噻二嗪类化合物及其应用 |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006016548A1 (ja) | 2004-08-09 | 2006-02-16 | Eisai R & D Management Co., Ltd. | ヘテロ環化合物を含有する新規な抗マラリア剤 |
| NZ566036A (en) | 2005-09-13 | 2010-06-25 | Janssen Pharmaceutica Nv | 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor |
| ES2274729B1 (es) | 2005-11-11 | 2008-06-01 | Consejo Superior Investig. Cientificas | Derivados de 5-carboxilato y 5-carboxamida 2-sustituidos de 1,1-dioxo-1,2,6-tiadiazina con propiedades cannabinoides. |
| US20100298314A1 (en) | 2006-12-20 | 2010-11-25 | Schering Corporation | Novel jnk inhibitors |
| MX2010003155A (es) | 2007-10-04 | 2010-04-01 | Hoffmann La Roche | Derivados de ciclopropil aril amida y uso de los mismos. |
| MX2010003156A (es) | 2007-10-04 | 2010-04-01 | Hoffmann La Roche | Derivados de aril amida substituida con tetrazol y usos de los mismos. |
| KR20100124272A (ko) | 2008-02-07 | 2010-11-26 | 아보트 러보러터리즈 | 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법 |
| AR070936A1 (es) | 2008-03-19 | 2010-05-12 | Janssen Pharmaceutica Nv | 1,2,4 -triazoles trisustituidos |
| EP2110377A1 (en) | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| WO2009127678A1 (en) | 2008-04-17 | 2009-10-22 | Glaxo Group Limited | Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71 |
| JP5486591B2 (ja) | 2008-05-09 | 2014-05-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アセチルコリン受容体モジュレーターとしての三置換ピラゾール |
| CA2725940A1 (en) | 2008-05-30 | 2009-12-23 | Merck Sharp & Dohme Corp. | Novel substituted azabenzoxazoles |
| EP2488520B1 (en) * | 2009-10-13 | 2015-09-02 | Merck Sharp & Dohme B.V. | Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor |
| EP3795573B1 (en) | 2009-12-31 | 2022-07-06 | Hutchison Medipharma Limited | Certain triazolopyrazines, compositions thereof and methods of use therefor |
| WO2012042915A1 (en) | 2010-10-01 | 2012-04-05 | Raqualia Pharma Inc. | Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists |
| SG192078A1 (en) * | 2011-02-03 | 2013-08-30 | Lupin Ltd | Pyrrole derivatives used as modulators of alpha7 nachr |
| US9617210B2 (en) * | 2013-03-13 | 2017-04-11 | Lupin Limited | Pyrrole derivatives as alpha 7 NACHR modulators |
| AR107928A1 (es) * | 2016-03-22 | 2018-06-28 | Merck Sharp & Dohme | Moduladores alostéricos de receptores de acetilcolina nicotínicos |
| US10870630B2 (en) | 2016-11-01 | 2020-12-22 | Merck Sharp & Dohme Corp. | Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
| WO2018112204A1 (en) | 2016-12-14 | 2018-06-21 | Cephalon, Inc. | Spiropiperidine derivatives |
| SG11201908012SA (en) | 2017-03-02 | 2019-09-27 | Assembly Biosciences Inc | Cyclic sulfamide compounds and methods of using same |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
-
2018
- 2018-07-13 HU HUP1800249A patent/HU231414B1/hu unknown
-
2019
- 2019-06-27 TW TW108122604A patent/TWI827628B/zh active
- 2019-07-12 US US17/259,975 patent/US12194050B2/en active Active
- 2019-07-12 CA CA3104264A patent/CA3104264A1/en active Pending
- 2019-07-12 WO PCT/IB2019/055949 patent/WO2020012423A1/en not_active Ceased
- 2019-07-12 CN CN201980046660.4A patent/CN112424198A/zh active Pending
- 2019-07-12 BR BR112020027016-4A patent/BR112020027016A2/pt unknown
- 2019-07-12 IL IL279939A patent/IL279939B2/en unknown
- 2019-07-12 SG SG11202012769QA patent/SG11202012769QA/en unknown
- 2019-07-12 AR ARP190101992A patent/AR115783A1/es unknown
- 2019-07-12 EP EP19744869.9A patent/EP3820865A1/en active Pending
- 2019-07-12 PE PE2021000052A patent/PE20210465A1/es unknown
- 2019-07-12 KR KR1020217004286A patent/KR20210033003A/ko not_active Ceased
- 2019-07-12 GE GEAP202215558A patent/GEAP202215558A/en unknown
- 2019-07-12 AU AU2019300515A patent/AU2019300515B2/en not_active Expired - Fee Related
- 2019-07-12 MX MX2021000461A patent/MX2021000461A/es unknown
- 2019-07-12 JP JP2021500540A patent/JP7440486B2/ja active Active
- 2019-07-12 CU CU2020000109A patent/CU24622B1/es unknown
- 2019-07-12 GE GEAP201915558A patent/GEP20237459B/en unknown
- 2019-07-12 EA EA202190246A patent/EA202190246A1/ru unknown
- 2019-07-12 MY MYPI2020006712A patent/MY207757A/en unknown
-
2021
- 2021-01-04 PH PH12021550007A patent/PH12021550007A1/en unknown
- 2021-01-12 CL CL2021000081A patent/CL2021000081A1/es unknown
- 2021-02-03 CO CONC2021/0001224A patent/CO2021001224A2/es unknown
-
2024
- 2024-02-14 JP JP2024020524A patent/JP2024056879A/ja not_active Withdrawn
- 2024-11-14 US US18/947,529 patent/US20250064823A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5966014B2 (ja) | 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用 | |
| JP4198989B2 (ja) | セロトニン作動性薬 | |
| TW200911255A (en) | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 | |
| JP2021529813A5 (https=) | ||
| DE69123286T2 (de) | Verwendung von 5-HT1A Rezeptoragonisten zur Hemmung der Magensäuresekretion | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2010518026A5 (https=) | ||
| JP2010053153A (ja) | Ｃｂ１受容体拮抗剤の経口用医薬組成物 | |
| JP2001506231A (ja) | ヘテロ環式チオエステルおよびケトン | |
| JP2008500336A (ja) | 治療化合物：骨格としてのピリジン | |
| JPWO2007105753A1 (ja) | トリアゾール誘導体またはその塩 | |
| CN1283183A (zh) | 具有mmp和tnf抑制活性的异羟肟酸和羧酸衍生物 | |
| JP2012502980A5 (https=) | ||
| JP2021531260A5 (https=) | ||
| JP2005526835A (ja) | 新規な２−置換−１，３−チアゾール化合物 | |
| JP6023926B2 (ja) | 認知症治療のための５−ｈｔ４受容体アゴニスト | |
| JPWO2020012423A5 (https=) | ||
| JP2021529813A (ja) | チアジアジン誘導体 | |
| JP2015521643A5 (https=) | ||
| JP2000302680A (ja) | 脳保護剤 | |
| KR20080089413A (ko) | 카나비노이드 ｃｂ1 수용체 조절자로서의4,5-디하이드로-(1ｈ)-피라졸 유도체 | |
| JP2004529936A5 (https=) | ||
| JPWO2020012422A5 (https=) | ||
| JP2019535715A5 (https=) | ||
| WO2005100341A1 (ja) | ２－アミノピリミジン誘導体 |